公开(公告)号：EP3180331B1

公开(公告)日：2022-06-08

申请号：EP15754099.8

申请日：2015-08-14

发明人： AUSTAD, Brian Clinton ,  ROE, David G.

IPC分类号： C07D403/12 ,  A61K31/497 ,  A61P35/00 ,  A61P25/00 ,  A61P31/00

公开(公告)号：EP3010892B8

公开(公告)日：2019-05-22

申请号：EP14738998.5

申请日：2014-06-20

申请人： Karyopharm Therapeutics Inc.

发明人： BALOGLU, Erkan ,  SHACHAM, Sharon ,  MCCAULEY, Dilara ,  KASHYAP, Trinayan ,  SENAPEDIS, William ,  LANDESMAN, Yosef ,  GOLAN, Gali ,  KALID, Ori ,  SHECHTER, Sharon

IPC分类号： C07D249/08 ,  A61K31/497 ,  A61P35/00

公开(公告)号：EP3337796A1

公开(公告)日：2018-06-27

申请号：EP16756922.7

申请日：2016-08-17

申请人： Karyopharm Therapeutics, Inc.

发明人： BALOGLU, Erkan ,  SHACHAM, Sharon ,  SENAPEDIS, William

IPC分类号： C07D405/14 ,  A61K31/444 ,  C07D413/14 ,  C07D409/14 ,  C07D401/14 ,  A61K31/4436 ,  A61K31/443 ,  A61K31/4439 ,  A61P35/00 ,  A61P17/02 ,  A61P25/28 ,  A61P29/00

CPC分类号： C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14

摘要： The invention generally relates to cyclic compounds and, more particularly, to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T- Cell mediated autoimmune diseases) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP2542089B1

公开(公告)日：2017-01-18

申请号：EP11751491.9

申请日：2011-03-05

申请人： Karyopharm Therapeutics, Inc.

发明人： SHACHAM, Sharon ,  KAUFFMAN, Michael ,  SANDANYAKA, Vincent, P. ,  SHECHTER, Sharon

IPC分类号： C07D401/14 ,  C07D231/12 ,  C07D233/64 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D249/08 ,  C07D203/06 ,  C07D203/04 ,  C07D207/337 ,  C07D403/12 ,  C07D401/04 ,  C07D403/04 ,  C07D403/06 ,  C07D417/04 ,  C07D257/04

CPC分类号： C07D409/04 ,  A61K31/4196 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/505 ,  C07D207/337 ,  C07D231/12 ,  C07D233/64 ,  C07D249/08 ,  C07D257/04 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D417/04 ,  C07D417/12

公开(公告)号：EP3010892A1

公开(公告)日：2016-04-27

申请号：EP14738998.5

申请日：2014-06-20

申请人： Karyopharm Therapeutics, Inc.

发明人： BALOGLU, Erkan ,  SHACHAM, Sharon ,  MCCAULEY, Dilara ,  KASHYAP, Trinayan ,  SENAPEDIS, William ,  LANDESMAN, Yosef ,  GOLAN, Gali ,  KALID, Ori ,  SHECHTER, Sharon

IPC分类号： C07D249/08 ,  A61K31/497 ,  A61P35/00

CPC分类号： C07D401/06 ,  C07D249/08 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

摘要： The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula (I) or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

摘要翻译： 本发明涉及式（I）化合物及其药学上可接受的盐，包含式（I）化合物或其药学上可接受的盐的药物组合物，以及在治疗各种疾病中使用所述化合物，盐和组合物的方法 与CRM1活动相关。

公开(公告)号：EP2665362B1

公开(公告)日：2016-03-30

申请号：EP12736172.3

申请日：2012-01-16

申请人： Karyopharm Therapeutics, Inc.

发明人： SANDANAYAKA, Vincent, P. ,  SHACHAM, Sharon ,  SHECHTER, Sharon ,  MCCAULEY, Dilara

IPC分类号： C07D413/14 ,  C07D401/06 ,  C07D403/06 ,  C07D413/06 ,  C07D417/06 ,  C07D249/08 ,  A61K31/41 ,  A61P35/00

CPC分类号： C07D249/08 ,  C07D401/06 ,  C07D403/06 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06

公开(公告)号：EP2665362A1

公开(公告)日：2013-11-27

申请号：EP12736172.3

申请日：2012-01-16

申请人： Karyopharm Therapeutics, Inc.

发明人： SANDANAYAKA, Vincent, P. ,  SHACHAM, Sharon ,  SHECHTER, Sharon ,  MCCAULEY, Dilara

IPC分类号： A01N43/64 ,  A61K31/41

CPC分类号： C07D249/08 ,  C07D401/06 ,  C07D403/06 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06

摘要： The invention generally relates to the field of nuclear transport modulators,
e.g. , CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions,
e.g. , in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

公开(公告)号：EP2542089A1

公开(公告)日：2013-01-09

申请号：EP11751491.9

申请日：2011-03-05

申请人： Karyopharm Therapeutics, Inc.

发明人： SHACHAM, Sharon ,  KAUFFMAN, Michael ,  SANDANYAKA, Vincent, P. ,  SHECHTER, Sharon

IPC分类号： A01N57/00

CPC分类号： C07D409/04 ,  A61K31/4196 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/505 ,  C07D207/337 ,  C07D231/12 ,  C07D233/64 ,  C07D249/08 ,  C07D257/04 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D417/04 ,  C07D417/12

摘要： The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).